Literature DB >> 11869324

Prognostic value of laparoscopic ultrasound in patients with gastro-esophageal cancer.

M E Flett1, M N Lim, D Bruce, S H Campbell, K G Park.   

Abstract

Forty-four patients with gastro-esophageal tumors regarded as resectable by conventional staging underwent laparoscopic ultrasonography (LUS). Following LUS, seven were found to be irresectable and were managed by palliative therapies. Thirty-seven patients proceeded to surgical exploration and 36 were resected (R0 80%, R1 11%, and R2 9%). All patients were reviewed until death or for a minimum of 24 months. Patients undergoing resection had a 62% 1-year survival (median 17 months; confidence intervals, CI 6-28). LUS defined nodal status indicated a trend toward prolonged survival in the node-negative group, median 22 months (CI 5-39), compared with 13 months (CI 6-20) in the node-positive group. Disease-free survival was greater in LUS node-negative patients at 29 months (CI 23-35) compared with node-positive patients at 13 months (CI 5-21) P=0.0083. LUS staging allows prediction of the likelihood of recurrence of gastro-esophageal malignancies. This may prove useful for the appropriate allocation of patients to primary and adjuvant therapies.

Entities:  

Mesh:

Year:  2001        PMID: 11869324     DOI: 10.1046/j.1442-2050.2001.00188.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  3 in total

1.  [Laparoscopic ultrasound].

Authors:  D Wilhelm; H Feussner
Journal:  Chirurg       Date:  2007-05       Impact factor: 0.955

2.  Combined pretherapeutic endoscopic and laparoscopic ultrasonography may predict survival of patients with upper gastrointestinal tract cancer.

Authors:  Michael Bau Mortensen; Claus Fristrup; Alan Ainsworth; Henning Overgaard Nielsen; Torsten Pless; Claus Hovendal
Journal:  Surg Endosc       Date:  2010-07-30       Impact factor: 4.584

Review 3.  [Staging laparoscopy in oncology].

Authors:  H Feussner; F Härtl
Journal:  Chirurg       Date:  2006-11       Impact factor: 0.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.